Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857294 | 0.93 | HRH2 (0.57) | ALDH1A1KDM4ETDP1MAPTHRH2 | |
| SCHEMBL16088361 | 0.89 | KDM4E (0.67) | ALDH1A1KDM4ETDP1MAPTHRH2 | |
| Hydrochloric Acid SCHEMBL16054922 | 0.88 | KDM4E (0.66) | ALDH1A1KDM4ETDP1MAPTHRH2 | |
| SCHEMBL17087197 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KDM4ETDP1MAPTKCNJ1 | |
| Hydrochloric Acid SCHEMBL7362832 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4ETDP1MAPTKCNJ1 | |
| SCHEMBL315786 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KDM4ETDP1MAPTHRH2 | |
| SCHEMBL13778102 | 0.83 | KCNA5 (0.50) | ALDH1A1KDM4EHRH3RAB9A | |
| SCHEMBL6285686 | 0.82 | HRH2 (0.60) | ALDH1A1KDM4ETDP1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL16107158 | 0.81 | HRH3 (0.62) | ALDH1A1KDM4ETDP1MAPTHRH2 | |
| SCHEMBL520019 | 0.81 | LTA4H (0.72) | ALDH1A1KDM4ETDP1MAPTHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| CN-102026993-A | New compounds III | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | disclosed |
| CN-102015668-A | Piperazine derivatives and their use as leptin receptor modulators | ASTRAZENECA AB PUBL | 2011-04-13 | — | — | CN | disclosed |
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | ALDH1A1 2912/4885KDM4E 3319/4885TDP1 4797/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | ALDH1A1 2717/4885KDM4E 3606/4885TDP1 4792/4885 |
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | ALDH1A1 2629/4885KDM4E 2572/4885TDP1 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.